Nureca Share Price

NSE
NURECA •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Nureca
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
Near 52W Low of ₹222.00
-19
Dividend yield 1yr %
0

Nureca Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Nureca Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
26.46 Cr
31.19 Cr
20.27 Cr
16.97 Cr
22.37 Cr

Nureca Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
102.44 Cr
118.43 Cr
263.24 Cr
216.27 Cr
101.79 Cr

Nureca Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
-2.8 Cr
-0.48 Cr
1.66 Cr
-4.15 Cr
0.16 Cr

Nureca Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
-1.79 Cr
-8.25 Cr
44.96 Cr
46.37 Cr
6.41 Cr
Nureca Result Highlights
  • Nureca Ltd reported a 18.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 1.2%.

  • Its expenses for the quarter were down by 9.4% QoQ and up 14.2% YoY.

  • The net profit increased 483.3% QoQ and decreased 1850.0% YoY.

  • The earnings per share (EPS) of Nureca Ltd declined at 2.8 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Nureca shareholding Pattern

Promoter
64.1%
Foreign Institutions
0.4%
Public
35.5%
Promoter
63.8%
Foreign Institutions
0.7%
Public
35.5%
Promoter
63.2%
Foreign Institutions
0.1%
Public
36.6%
Promoter
63.2%
Foreign Institutions
0.1%
Public
36.7%
Promoter
63.2%
Foreign Institutions
0.1%
Public
36.7%
Promoter
63.2%
Foreign Institutions
0.1%
Public
36.6%

Nureca Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
233.10
10Day EMA
238.30
12Day EMA
240.70
20Day EMA
250.70
26Day EMA
257.50
50Day EMA
274.90
100Day EMA
287.60
200Day EMA
299.50
5Day SMA
234.50
10Day SMA
235.30
20Day SMA
250.40
30Day SMA
261.20
50Day SMA
296.90
100Day SMA
290.80
150Day SMA
300.30
200Day SMA
293.00
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
8786 Rs
8786 Rs
Week Rs
9571 Rs
9571 Rs
Month Rs
8392 Rs
8392 Rs
Resistance & Support
231.40
Pivot
Resistance
First Resistance
233.81
Second Resistance
238.40
Third Resistance
240.81
Support
First Support
226.81
Second support
224.40
Third Support
219.81
Relative Strength Index
32.92
Money Flow Index
35.36
MACD
-16.80
MACD Signal
-16.96
Average True Range
13.19
Average Directional Index
29.96
Rate of Change (21)
-15.59
Rate of Change (125)
-31.96

Nureca Company background

Founded in: 2016
Managing director: Saurabh Goyal
The Company was formerly incorporated as Nureca Private Limited in India on 02 November 2016 under the provisions of Companies Act, 2013. The Company got converted from Private Limited Company to a Public Limited Company with effect from 08 July 2020 and the name of Company was changed to Nureca Limited. The Company is engaged in the business of home healthcare and wellness products. The Company is a leading healthcare and wellness company with a product range of over 150 SKUs across different categories. The flagship brands such as Dr. Trust continue to enjoy high credibility and a loyal customer base. The products comply with USFDA, European CE, ROHS and ISO certifications, which reinforce customers belief in their products. At present, the Company holds more than 100 design products. Nureca is a digital first, B2C company. The Company sell products through implementation of various digital online platform channels like Flipkart, Amazon and website http://drtrust.in/. Dr. Trust is a pioneer in global healthcare and wellness brand with patented technologies and innovative solutions, helping users monitor chronic ailments. The Company is committed to creating products that support diagnosis, treatment and prevention of illness through monitoring and analysis of health data. Nurecas products are manufactured to be safe, accurate, longlasting, and compliant with national and international regulations. The Companys growing range of connected devices is well entrenched in IoT and easy to sync with smart devices, while health app provides secure consolidation of data.The Company is focused on leveraging its innovation, research, and data science capabilities to help and empower more people living with chronic and lifestyle diseases to live healthier and happier lives. The Company envisaged digital ecosystem and principles aims to provide integrated solutions aiding customers to maintain a suitable fitness regime, have clear understanding of and control over existing diseaseswith easier health monitoring at home and optimum nutrition through quality nutraceuticals.In 2017, the Company commenced business operations and launched Dr. Trust brand through digital healthcare channel.In 2018, the Company widened product basket with launching of brands in electric massages and mother child care categories like Dr. Physio and Trumom. The Company started three flex centers in Punjab, Karnataka and Uttar Pradesh. In 2019, the Company took the initiative for commencing business with WS retail. It increased the aggregate number of SKUs to 150. The Company added three flex centers in Tricity Chandigarh, Telangana and Maharashtra. The Companys key products secured a warehouse drug license.In 2020, Company expanded presence through different channels and took initiative for starting business with 1mg, Pharmeasy, Paytm, and Croma retail stores. The Company had taken the effect of demerger as per the Scheme of Arrangement among Nectar Biopharma Private Limited (demerged company) and Nureca Private Limited (resulting company) and their respective shareholders and creditors under Section 230 to 232 and other applicable provisions of the Companies Act 2013, which has been sanctioned by the Honorable National Company Law Tribunal (NCLT), Mumbai vide its Order dated 29 April 2020. The Scheme had become effective on 23 May 2020 (Effective date) on filing of certified copy of the Order with the Registrar of Companies. The Appointed Date from which the Scheme was operative was 1 April 2019. Pursuant to the Scheme of Demerger, certain portion of business activities of the demerged company was transferred by Nectar Biopharma Private Limited from the Appointed date of 1 April 2019.In FY 2021, the Company received prestigious Economic Times Best Healthcare Brands Award 2021.
Read More

Nureca FAQs

Nureca share price is ₹229.21 in NSE and ₹230 in BSE as on 12/3/2025.

Nureca share price in the past 1-year return was -19.77. The Nureca share hit a 1-year low of Rs. 222 and a 1-year high of Rs. 447.5.

The market cap of Nureca is Rs. 229.21 Cr. as of 12/3/2025.

The PE ratios of Nureca is 0 as of 12/3/2025.

The PB ratios of Nureca is 1.18 as of 12/3/2025

You can easily buy Nureca shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Nureca stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -